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Background: A plethora of mobile health applications (m-health apps) to support healthcare 
are available for both patients and healthcare professionals (HCPs) but content and quality vary 
considerably and few have undergone formal assessment.  
Objective: To systematically review the literature on m-health apps for managing atrial 
fibrillation (AF) that examine the impact on knowledge of AF, patient and HCP behaviour, 
patients’ quality-of-life, and user engagement. 
Methods: MEDLINE, EMBASE, CINAHL, and PsychInfo were searched from 1 January 
2005 to 5 September 2019, with hand-searching of clinical trial registers and grey literature. 
Studies were eligible for inclusion if they reported changes in any of: (1) Knowledge of AF; 
(2) Provider behaviour (e.g. guideline adherence); (3) Patient behaviour (e.g. medication 
adherence); (4) Patient quality-of-life; (5) User engagement. Two reviewers independently 
assessed articles for eligibility. A narrative review was undertaken as included studies varied 
widely in their design, interventions, comparators and outcomes. 
Results: Seven studies were included; six m-health apps aimed at patients and one at HCPs. 
m-health apps ranged widely in design, features, and method of delivery. Four studies reported 
patient knowledge of AF; three demonstrated significant knowledge improvement post-
intervention or compared to usual care.  One study reported greater HCP adherence to oral 
anticoagulation guidelines after m-health app implementation.  Two studies reported on patient 
medication adherence and quality-of-life; both showed improved quality-of-life post-
intervention but only one observed increased adherence. Regarding user engagement, five 
studies reported patient perspectives on usability, three on acceptability, and one on feasibility; 
overall all m-health apps were rated positively. 
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Conclusion: m-health apps demonstrate improvements in patient knowledge, behaviour and 
quality of life.  Studies formally evaluating the impact of m-health on HCP behaviour are scarce 
and larger-scale studies with representative patient cohorts, appropriate comparators and 




The use of mobile health (m-health), primarily via smartphones, has the potential to allow 
wider dissemination of healthcare and could also support traditional healthcare delivery by 
promoting greater interaction between patients and healthcare professionals (HCPs).1, 2   
Over the last decade there has been an explosion of m-health applications (m-health apps), with 
an estimated 3.7 billion downloaded globally between 2013 and 2017,3 including many for 
atrial fibrillation (AF) but very few have undergone formal assessment.4-6  Hence, the 
magnitude and impact of m-health apps for AF, and the degree of patient and HCP engagement 
and acceptability, are currently unknown.  Given that patients and HCPs can easily access these 
apps, it is important to have some sense of their scope and content, acceptability to users and 
additionally, to examine the purpose of, and outcomes of, app implementation and usage. To 
date, no systematic review has evaluated the impact of the variety of m-health apps currently 
available for patients with AF and HCPs who manage this condition.  Therefore, the current 
review will systematically assess this literature to examine the impact on knowledge of AF, 





This systematic review was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses (PRISMA) guidelines.7 A completed PRISMA 
checklist is provided in the supplementary material.  
Criteria for considering studies for the review 
Studies carried out in any setting and designed to evaluate m-health apps were eligible for 
inclusion. We included primary research which evaluated the effects of any m-health app for 
AF which was designed to enhance patient and/or HCP education, improve communication 
between patients and HCPs, or to encourage active patient involvement in the management of 
their condition. All types of study designs were considered with the exception of purely 
qualitative studies. Ongoing studies were considered and are presented in a separate table. We 
excluded e-health or m-health apps that only screened for or monitored AF, and remote 
monitoring of AF via ECG/implantable devices. 
Participants 
Adults (18 years and older) with AF and/or HCPs managing patients with AF were eligible for 
inclusion. Studies with mixed population groups which included patients with AF were also 
eligible for inclusion in this review, provided the majority were AF patients, and/or data 
regarding AF patients alone was available. 
Interventions 
Interventions designed to manage AF via the use of m-health apps (e.g. mobile devices, such 
as mobile phones, patient monitoring devices, personal digital assistants (PDAs), and other 
wireless devices etc.) were eligible for inclusion. 
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Comparators 
Any comparator or usual care (i.e. no intervention) could be included. 
Outcomes 
Studies were eligible for inclusion in the review if they reported changes in any of the 
following outcomes: (1) Knowledge of AF (patient and/or HCP); (2) HCP behaviour (e.g. 
adherence to AF management guidelines); (3) Patient behaviour (e.g. medication adherence); 
(4) Patient quality-of-life.  Studies were also eligible for inclusion if they reported only 
process outcomes e.g. user engagement and perspectives on acceptability and usage patterns 
of the m-health app, but not if they were solely qualitative in nature. 
Search strategy 
The search strategy was developed by the research team.  Medical Subject Headings and 
keywords such as atrial fibrillation, mobile health, smartphone, mobile applications, etc. were 
used (see Supplementary Table 1) to search bibliographic databases.  MEDLINE, EMBASE, 
CINAHL, and PsychInfo were searched from 1 January 2005 to 5 September 2019 for relevant 
studies.  We restricted the publication date to the year 2005 onwards as m-health is a relatively 
new phenomenon, and also to capture only the more recent and relevant empirical research 
reflective of changes in clinical practice guidelines around stroke prevention for AF. There 
were no language restrictions. Availability of the full-text publication was a requirement. 
Reference lists of included studies were manually searched.  Additional unique records were 
identified through hand-searching trials registers (Cochrane Central Register of Controlled 
Trials, Clinical Trials (www.clinicaltrials.gov) and ISCTRN (www.isrctn.com/) by entering 
key search terms (e.g., atrial fibrillation, mobile health, smartphones etc.) into the websites 
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search function. Grey literature was addressed by contacting key opinion leaders for 
unpublished data. Search results were managed using Covidence. 
Study selection 
Two reviewers (DL/NM) independently screened the titles and abstracts against the search 
criteria.  The full texts of all potentially relevant articles were retrieved and independently 
assessed by both reviewers. Disagreements were resolved through discussion and assessment 
by a third reviewer (JG). 
Data extraction 
Data were extracted by one reviewer (DL) and checked by another reviewer (JW). The 
following information was extracted: (i) authors, year, country; (ii) study aim; (iii) study 
characteristics (study design and sample size); (iv) participant characteristics (age, sex, 
ethnicity, comorbidities); (v) intervention (type of m-health delivery, features of the app/m-
health, duration, frequency, providers, target users, follow-up points); (vi) comparator(s) (usual 
care, description of usual care, no intervention); and (vii) outcomes (patients’ and/or HCP’s 
knowledge of AF, HCP behaviour (e.g. adherence to AF management guidelines), patient 
behaviour (e.g. medication adherence), patient quality-of-life, and user engagement and 
perspectives on acceptability). 
Risk of bias assessment 
Assessment of risk of bias in individual studies was undertaken independently by two reviewers 
(DL/JG) utilising the Cochrane risk of bias tool8 for randomised controlled trials and the Risk 
of bias tool for non-randomised studies,9 as appropriate. 
Data synthesis 
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Given that the included studies varied widely in their design, interventions, comparators and 
outcomes, no synthesis was undertaken and we report a narrative review. 
 
RESULTS 
The searches identified 11,152 citations (see Figure 1).  After removal of duplicates 
(n=2223), the titles and abstracts of 8929 articles were independently assessed by two 
reviewers.  Of these, 52 were deemed to be potentially relevant and were assessed for 
eligibility in their full text; 43 were excluded and 2 studies were on-going.10, 11 A full list of 
the excluded studies and the reason for exclusion are provided in the Supplementary 
materials (see Supplementary Table 2).  No relevant studies were identified via hand-
searching. As a result, seven studies4-6, 12-15 were included (see Table 1). 
Characteristics of the included studies 
The included studies were published between 2017 and 2019 and comprised between 1013, 15 
and 2096 participants, with a total of 466 patients4-6, 12-14 (mean age ranged from 5914 to 716 
years; 50%13 to 67%5 male) and 10 HCPs (mean age 43.8 years; 30% men).15  Studies were 
conducted in Belgium (n=2),4, 5 China (n=1),6 Iran (n=1),15 Poland (n=1),12 and the USA 
(n=2).13, 14  Six studies were m-health apps aimed at patients4-6, 12-14 all of whom had AF (not 
exclusively AF in one study12), with one targeting HCPs.15  Only one study6 had m-health 
apps directed at both patients and HCPs, but this study only reported outcome data for 
patients.  The studies varied widely in design with one cluster-randomised pilot study;6 one 
prospective, randomised controlled trial;4 two before-and-after studies;12, 15 and three 
exploratory/feasibility pilot studies.5, 13, 14 Most studies had short follow-up periods, between 
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4-weeks13, 14 and 3-months,4-6 with only two studies following participants for longer (6-
months15 and 1-year12). 
Types of interventions 
The interventions varied markedly in their design, features of the m-health app, and method 
of delivery (see Table 1).  Three were delivered via an app on a mobile phone only,6, 12, 13 and 
four via mobile phone or tablet.4, 5, 14, 15 Two studies were patient education interventions,4, 12 
two were patient behaviour change interventions utilising support and adherence apps,13, 14 
two supported HCP behaviour change6, 15 although one of the two6 did not report the outcome 
data related to the HCP app, and two were multi-faceted  apps incorporating patient 
behaviour change and education interventions.5, 6  
The one m-health app designed for HCPs (cardiologists) was a computerised decision-
support system (CDSS) to help improve adherence to oral anticoagulation (OAC) guidelines, 
using an app to calculate the CHA2DS2-VASc, and HAS-BLED scores and to provide OAC 
treatment recommendations based on clinical guidelines.15  
One study12 used oculus glasses (virtual reality headset) and a smartphone to deliver patient 
education on risk of stroke and use of OAC for stroke prevention via a 3D movie, while 
another, the miAfib app, assessed AF symptoms and mood throughout the day.13  The mAF 
app6 included a patient version and a doctor version, containing clinical decision-support 
tools (CHA2DS2-VASc, HAS-BLED, SAMe-TT2R2) linked to patient health records, patient 
educational materials (8 topics), and tools to engage and support patients in self-care (e.g., 
heart rate and blood pressure monitoring) and structured follow-up.  
Hirschey and colleagues14 developed an app for patients’ use on smartphones or tablets, to 
provide information on AF and OAC via text and animated videos, with a log for patients to 
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record AF episodes and related notes, triggers for AF, medication and appointment 
reminders, heart rate monitor, and health-related news feed.  
The Health Buddies app5 teamed up AF patients and their grandchildren and recorded 
performance of ‘healthy’ daily tasks, such as intake of OAC (non-vitamin K antagonist OAC, 
NOAC) and heart rate monitoring for the AF patients (grandparents) and eating fruit or 
brushing teeth twice a day for the ‘buddies’ (grandchildren).  The app rewarded performance 
of these daily tasks with access to educational quizzes for the patients and educational games 
for the grandchildren. Completion of daily tasks for a 3-month period was rewarded with a 
joint trip or fun activity for the grandparents and grandchildren. Another study by the same 
research group utilised an on-line tailored education platform on AF and procedure-related 
information for patients undergoing pulmonary vein isolation or electrical cardioversion, 
accessed using a unique log-in.4  
Types of comparators 
One study compared the intervention to usual care only;6 one compared the app to standard 
care with internet access but no structured intervention, and standard care with no internet 
access;4 two were before-and-after studies,12, 15 and three studies did not have a comparison 
group.5, 13, 14  Usual care consisted of information from a cardiologist and booklets4, and 
consultation with a cardiologist.6 
Types of outcomes 
 Four studies reported on patient knowledge of AF,4-6, 12 with only one reporting patient 
knowledge of OAC.12 No study reported on the knowledge of HCPs.  Only one study15 
reported on HCP behaviour, focussing on adherence to OAC guidelines.  Three of the four 
studies that examined the impact of m-health apps on patient knowledge demonstrated a 
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significant improvement on knowledge of AF and/or OAC after the intervention12 or 
compared to usual care4, 6 (see Table 1). Desteghe et al5 reported a non-significant (p=0.09) 
increase in knowledge level from baseline to 3-months post-intervention. The only study that 
reported the effect of the m-health app on HCP behaviour showed a significant improvement 
in guideline-adherent OAC treatment following the intervention (48% pre-intervention vs. 
65.5% post-intervention; p<0.0001).15 
Two studies reported on patient adherence to medication.5, 6 One6 reported a significant 
increase in drug adherence at 1- and 3-months in the intervention group (both p<0.001) 
measured using the Pharmacy Quality Alliance adherence measure, while the other study5 
showed a reduction in adherence from 88.6% (SD 15.4%) to 81.8% (SD 18.7%) measured 
using an electronic medication monitor. 
Two studies reported on patient’s quality-of-life.4, 6  Guo et al6 measured quality-of-life using 
the visual analogue scale of the EQ-5D16 and reported a significant improvement from 
baseline to 1-month and 3-months in the intervention group compared to usual care (all 
p<0.05). Desteghe4 assessed quality-of-life using the AFEQT.17 This demonstrated 
significant improvements at 6- and 12-weeks post-procedure compared to baseline in the m-
health app group and the comparator who had access to the internet, but not in the usual care 
group.  
Five studies investigated user engagement with the m-health app,4-6, 13, 14 with three assessing 
perspectives on acceptability,4, 6, 14 five on usability,4-6, 13, 14 and one on feasibility.6  
Generally, patients found the m-health apps acceptable and usable. The two studies by 
Desteghe and colleagues4, 5 employed the User Experience Questionnaire18 to assess patient 
engagement with the apps.  The m-health app for tailored patient education rated positively 
on all aspects,4 whilst the Health Buddies app was rated positively only for clarity, novelty, 
 13 
stimulation and attractiveness.5 Three studies4, 5, 14 reported some negative aspects of their m-
health apps: software bugs reported by 7/12 (58%);14 10% were unable to use the device;4 
and 5/15 (33%) often encountered technical difficulties or problems.5 
Risk of bias assessment 
A summary of the risk of bias assessment is presented in Table 2, with more detailed 
explanation available in Supplementary Table 3.  Overall, most of the included studies had 
high or unclear risk of bias in relation to participant selection due to highly selected and often 
small sample sizes,5, 13, 14 the observational nature of the majority of the studies5, 13-15 and the 
lack of detail on the randomisation procedure6 or incomplete randomisation.4  Due to the 
nature of the interventions it was not possible to blind the participants or personnel to the 
treatment allocation, and outcome assessors were only blinded in one study.6  All included 
studies, with the exception of Sheibani et al15 had a high or unclear risk of selective reporting 
bias.  The degree of incomplete data reporting (attrition bias) varied and was low in three 
studies4, 5, 15 and unclear in two.12, 13 The main issues were related to not defining the primary 
outcome and/or the timing of the primary endpoint.  In the mAF app randomised controlled 
trial,6 42/113 (37.2%) people in the intervention group did not provide 3-month follow-up 
data compared to complete follow-up data in the usual care group and 4/16 (25%) of people 
enrolled in the study by Hirschey et al14 did not provide follow-up data.   
Excluded studies 
Supplementary Table 2 summarises the 43 excluded studies. Most (27/43 (62.8%)) studies 
were excluded as they were not an m-health intervention, four (4/43) reported outcomes 
which were outside the scope of the review, one (1/43) focused on a population without AF, 
one (1/43) was a systematic review, one (1/43) was a narrative review, three (3/43) were 
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editorials and one (1/43) was a protocol for a systematic review.  Five (5/43) were abstracts, 
four with no full-text available and one with full-text which was one of the included studies.12 
On-going studies 
Two protocol papers for ongoing studies were identified (see Table 3).  One study11 is testing 
an upgraded version of the mAF app,6 incorporating the ABC- (Avoid stroke, Better 
symptom management, and Cardiovascular and other comorbidities management) pathway 
compared to usual care in 3660 AF patients with CHA2DS2-VASc score≥2, in a cluster-
randomised controlled trial in China.  The second study, the Atrial Fibrillation health Literacy 
Information Technology Trial (AF-LITT)10 is a pilot RCT, exploring a 30-day smartphone 
intervention, based on an embodied conversational agent and the AliveCor Kardia device, 
compared to standard care (a symptom and adherence journal), in 180 AF patients receiving 
OAC, in the USA. 
 
DISCUSSION 
We have reported a systematic review of studies that have evaluated the impact of m-health 
apps for the management of AF on patient and HCP knowledge and behaviour, patient 
quality-of-life and user engagement with the app.  Despite the abundance of m-health apps 
available for healthcare, and AF specifically, only seven studies were eligible for inclusion in 
our systematic review. Of these, six were patient m-health apps.4-6, 12-14 Although the study by 
Guo et al6 reported both a patient and HCP version, outcome data was only presented relating 
to patient knowledge, behaviour, quality-of-life and app experience.  Notwithstanding the 
disparity in the design, features, and delivery of the m-health interventions, overall the 
various apps improved patient knowledge on AF and OAC compared to baseline12 or patients 
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receiving usual care,4, 6 improved patient medication adherence6 and quality-of-life,4, 6 
improved provider adherence to OAC guidelines15 and were positively rated for user 
engagement and acceptability.4-6, 13, 14  
However, many of the studies had limitations including very small sample sizes (15),5, 13-15 
lack of a comparator group,5, 13, 14 lack of blinding for outcome assessors,4, 5, 12-15 imprecision 
or lack of definition of, and timing of, primary (and secondary) outcomes,5, 12-14 short follow-
up periods for outcome evaluation (4-weeks14 to 3-months4-6), and incomplete reporting of 
outcome data.6, 14 This review has highlighted the need for larger, more comprehensive 
primary data collection studies with appropriate control groups, in diverse and representative 
AF patients, with longer-term follow-up, strategies to reduce attrition and ensure as complete 
as possible follow-up data, and more studies formally assessing the impact of m-health 
interventions on HCP knowledge and guideline-adherent AF management.  
A commentary on two European Society of Cardiology-endorsed apps, MyAF (Patient 
version) and AFManager (HCP version),19 was identified in our searches. However, these 
apps have yet to be formally tested for impact on patient and HCP knowledge and behaviour 
and were therefore not eligible for inclusion in this review.  The rapid integration and 
upscaling of mobile and e-technology in healthcare and everyday life does not negate the 
necessity for future m-health apps to demonstrate evidence of positive impacts on the 
outcomes they claim to support, to enable confidence in the end-user in their effectiveness 
and applicability. 
The promise of mobile health is to make health education and health-related resources 
accessible regardless of health literacy. Reading ability plays a vital part in health literacy. 
Therefore, it is mandatory to introduce health apps that are not only scientifically validated but 
also written at reading-grade levels not exceeding national standard recommendations.20 
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All included studies used essentially stand-alone m-health apps, rather than apps as part of an 
intervention package, although the complexity and content of the apps varied.  Four studies4, 
12, 13, 15 used the app to focus on delivery of one element (i.e., patient education,4, 12 patient 
self-monitoring and reporting of AF symptoms and mood,13 and stroke and bleeding risk 
assessment and OAC recommendation for physicians15 ) whereas the other three5, 6, 14 were 
more complex.  The Health Buddies app5 was an interactive game, involving patients’ 
grandchildren, to support medication adherence; the mAF app6 patient-version focussed on 
education but also incorporated patient self-support items, self-monitoring of heart rate and 
blood pressure and feedback on treatment; while the AFib Connect app14 included education, 
plus self-monitoring of heart rate, AF episodes and triggers, medication and appointment 
reminders, and a heart health-related news feed. These apps, as part of an intervention 
package, may be more, or less, effective than when used as the sole intervention; however, it 
is important to identify the active component(s) of interventions. 
Of the two on-going studies, one11 has reported the results of the ABC-pathway supported by 
the mAFA II app on the primary outcome of a composite of stroke/thromboembolism, all-
cause mortality, and rehospitalisation.21 Among the 1646 patients receiving the mAFA II-
supported intervention (mean age 67.0 years; 38% female), the rate of the composite endpoint 
was significantly lower (1.9% vs. 6.0%; hazard ratio (HR): 0.39; 95% confidence interval 
(CI): 0.22 to 0.67; p < 0.001) compared to those receiving usual care (n=1678; mean age 70.0 
years; 38% female).21 However, the impact of the m-health supported intervention on patient 
and HCP behaviour, patient knowledge and quality-of-life, is yet to be reported. The other 
on-going study, the AF-LITT,10 a pilot RCT of 180 AF patients receiving OAC, examining 
the impact of an embodied conversational agent and the AliveCor Kardia device for 30 days 
on health-related quality of life and self-reported adherence to OAC and app experience 
(patient and physician), is also still to report its findings. 
 17 
It is encouraging that several of the included studies involved contributions from patients and 
inter-disciplinary HCPs in the design and refinement of the patient apps;4, 5, 13, 14 co-designing 
interventions with end-users is beneficial and effective.22, 23  Since the main goal of m-health 
is to support and maintain (healthy) behaviour change, utilising interdisciplinary teams, 
including psychologists and social scientists with expertise in behavioural change 
intervention development and implementation is essential.  
m-health apps that include gamification features such as prizes, rewards, feedback on 
performance, competition, and social connectivity, have been shown to foster patient 
engagement and support adoption of healthy behaviours.24-26 Of the studies included in this 
systematic review, only one5 included gamification strategies within their app, such as 
rewards and communication with HCPs.  However, several of the apps included self-
regulatory behaviour change techniques, such as feedback and monitoring (including self-
monitoring),5, 13, 14 which are known to be effective for health promotion and secondary 
prevention.27, 28  
CONCLUSION 
Mobile health technology can be utilised to support the management of AF, and apps which 
have been formally evaluated demonstrate improvements in patient knowledge of AF and 
OAC, medication adherence, and quality-of-life, and greater guideline-adherent OAC 
management by cardiologists.  However, there is a dearth of studies formally evaluating the 
impact of m-health on HCP behaviour. Larger-scale studies with representative patient 
cohorts, appropriate comparators and longer-term assessment of the impact (both potential 
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Figure 1: PRISMA flow diagram for study selection process 
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Study aim Study population Study design App Features of the 
App 









Effectiveness of 3D 
movie in teaching 
patients about 






Mean (SD) age: 63y 
(15); 38% women, 
62% history of AF 




Inclusion criteria: aged >18 
years 
 
Exclusion criteria: dementia 
 
Recruitment April 2016 to 
August 2016 
 
Questionnaire at baseline, 
immediately after viewing 




week, and 1-year 
Oculus glasses and 
smartphone with 3D 




available on Google 
Play and Appstore 
 















3D movie  
 
Information on 
risk of stroke and 






AF; (2) drugs 
may reduce 





3D movie to 
deliver 
information 
Knowledge that stroke 
was consequence of AF:  
Before movie 22/100 
(22.0%); 
Immediately after movie 
83/100 (93%); 
7-days later 74/94 (78.7%) 
1 year 64/90 (71.1%); all 
p<0.0001 
 
Knowledge that drugs 
may reduce stroke risk:  
Before: 83/94 (88.3%) 
Immediately after:  
1-week later: 94/94 
(100%); p<0.0001 
1 year: 87/90 (96.7%) 
(p=0.02) 
 
Knowledge that OAC 
reduces stroke risk: 
Before: 66/94 (70.2%) 
1-week later: 90/94 
(95.7%) 
1-year later: 83/90 
(92.2%); all p<0.0001 
 
Usefulness: 99/100 (99%) 
stated useful tool to 
increase awareness of 
consequences of AF 
 
3D movie was an 
effective tool in 
transferring 
knowledge about the 
consequences of AF 
and role of OAC in 
stroke prevention 
 
Negative aspects of 







and usefulness of 
mobile app designed 
12 AF pts 
  
Exploratory pilot study: 
naturalistic app use; surveys 
(in-person at baseline, then 
AFib Connect mobile 
app (Android & 
iPhone iOS) platforms 
AFib guide: 





app navigation (3 themes); 
clarity of app instructions 
Needs more research 
in larger, more 
diverse AF sample 
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 to support self-care 
and treatment 
adherence for AF 
patients prescribed 
NOACs 
Mean age: 59y 
(range 37-67y); 
7 (58.3%) men; 
100% Caucasian 
Mean AF duration: 
6y (range 1-15y); 
11/12 (92%) 
symptomatic; 11/12 




n=16 enrolled; 12 
completed study 
 
by post); 5 x 30 min semi-
structured weekly 
interviews to examine 
patients’ perceptions and 
everyday use of the app 




2016 to April 2017 
 
Purposive sampling of AF 
patients on NOACs, 
identified by clinician from 
1 hospital 
 
Participants reviewed app 
features at different time-
points and rated usability 
and usefulness over last 
week 
 
Patient satisfaction assessed 
on 5-point Likert scale, 
yes/no and open-ended 
questions 
 
Follow-up: weekly for 4-
weeks 
 
App developed based 
on semi-structured 
interviews and 
usability data from 











clinicians and patients 
using first version of 
app.  Feedback 
incorporated into 
design of version two, 
which was used for 
this study 
 










































and design intent; software 
bugs 
 
12/12 (100%) agreed 
somewhat or strongly that 
app was easy to use; only 
1/12 reported needing to 
ask for help when using 
App; 
 
App satisfaction: 92% 
reported being 
satisfied/very satisfied 
with the app 
 
Perceptions of app 
usefulness (3 variables): 
core needs of the patient 
segment; patient workflow 
while managing AFib; 
app’s ability to support the 
patient’s evolving needs 
 
10/12 somewhat or 
strongly agreed that the 
AFib app acted and felt 
like other apps they had 
used before 
 
App broadly useful 












Effectiveness of an 
on-line tailored 
education platform to 
inform AF patients 
undergoing DCCV or 
PVI 
120 AF pts. 
requiring DCCV or 
PVI 
 
Mean (SD) age: 
68.0y (10.2); 78 
(65%) male 
Prospective, randomised 




consecutive AF patients 
undergoing planned DCCV 
or PVI 
On-line patient 
education (general AF 
information, OAC & 
procedure-related 
information) 




unique log-in and 












Group 1 on-line tailored 
education group: 
significantly improved 
knowledge by end of 
hospitalisation (75.0% 










Exclusion criteria: <18 
years, severe mental (i.e. 
dementia) or physical (i.e. 
deafness) impairment, 
inability to read Dutch and 
not able to provide written 
informed consent 
 
Those with internet access 
allocated to: Group 1 on-
line education (n=35); or 
Group 2 standard care 
with on-line access (n=36)  
 
Those without computer/ 
tablet/smartphone (Group 3) 
received (3) standard care 
(n=49) 
 
JAKQ completed 1-3 weeks 
prior to hospitalisation, at 
hospitalisation and 6 and/or 
12-week post-procedure 
 
Standard care included 
information from 
cardiologist and specific 
and general information 
booklets 
 
Only those in Group 1 
received access to the on-
line tools 
 
Follow-up: Groups 1 and 2 
at baseline, at 
hospitalisation, 6- and 12-
months later 
 
Group 3: at hospitalisation 
and 3-months only 
physiologists based 
on hospital brochures 
& patient websites 
(AFA, EHRA, AHA, 




by text, images and 
movies.  Fact boxes 
highlighted key 
educational messages 
many times each 
patient visited 
platform, length 
of time viewing 
















Knowledge persisted at 6-
weeks (77.5% IQR 65.0-
85.0; p=0.010) and 12-
weeks (80.0% IQR 70.0-
90.0; p<0.001) after 
procedure 
Group 2 standard care with 
on-line access: No 
improvement in overall 
knowledge between 
baseline and time of 
hospitalisation (65.0% 
IQR 50.0-73.8; p=1.00).  
Significant improvement 
between baseline and 6-
week post-procedure 
(p=0.010) and between 
hospitalisation and 6-week 
post-procedure (p=0.016) 
 
Group 3 Standard care 
only: No knowledge 
improvement over course 
of study (p=0.248) 
 
Quality of life: Significant 
increase in overall AFEQT 
score in both on-line 
groups 6- and 12-weeks 
post-procedure compared 
to baseline and at 
hospitalisation 
 
Group 3: no significant 
difference in overall 




platform rated positively 
on all aspects 
 
level and higher risk 
of stroke and bleeding 
 










(CDSS) on improving 
adherence to 
anticoagulation 






10 cardiologists (7 
(70%) female) 








Interrupted times series 
design (before-&-after 
design) 
Setting: offices of 10 
cardiologists 
 
OAC guideline adherence 
assessed fortnightly from 
January 2016 to January 
2017; 6-months before and 
6-months after intervention 
 
Inclusion criteria: newly 
diagnosed AF patients 
 
Exclusion criteria: 
mechanical heart valve, 
severe mitral valve disease, 
any other reason for 
requiring anticoagulation 










CDSS designed for 
anticoagulant 









BLED score, gave 
treatment 
recommendations 










June 2016): 48% (n=212; 




2016-Jan 2017): 65.5% 
(n=207; 25 excluded due 
to missing data) 
 







guidelines for OAC 





interpretation of risk 
scores 
 
Negative aspects of 


















Mean (SD) age 
67.4; 57.5% male 
 
Usual care: n=96  
Mean (SD) age 
70.9y; 55.2% male 
 
Cluster randomised pilot 
study, 2 hospitals in China 
 
Recruitment 1 January to 1 
May 2017 
 
Inclusion criteria: aged 
≥18; confirmed AF (ECG or 
24-hr Holter) 
 
Exclusion criteria: <18y; 




































improved knowledge vs. 
UC (all p<0.05) 
 
Quality of life: 
Significantly increased in 
mAFA arm vs. UC at 
baseline (86.5 vs. 71.3), 1- 
(87.6 vs. 70.1) and 3-








reduction in OAC 
burden with mAFA 
vs. UC 
 
Most (90%) rated app 
as easy, user friendly, 
helpful 
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provide written informed 
consent  
 





























All assessed at 
baseline, 1- and 










Drug adherence: mAFA 
vs. UC: baseline (4 (4-11) 
vs. 4 (4-11); p=0.870); 1 
month (0 (0-4) vs. 4 (0-
11); p<0.001); 3 months 2 





expressed more OAC 
burden (all p<0.05); 
mAFA pts. reported 
significantly more OAC 
benefit at 1-month only 
(p=0.013) 
 
App usability: 90% 
reported app was easy, 
user friendly, helpful 
 
 
Negative aspects of 






Assess usability and 
feasibility of a mobile 
application to assess 
symptoms in patients 
with AF 
n=10 pts with PAF 
or persistent AF 
 
Age (NR) 




Pilot, feasibility study 
 
Inclusion criteria: >21y; AF 
diagnosis; stable medical 





psychiatric or neurological 
disorders; dementia, cancer, 
drug/alcohol abuse; life 
expectancy <1 year; 
pregnancy; existing 





interview at 4-week 
 
Follow-up: 4 weeks 
miAfib 
Mobile app (iPhone 






assist mobile app set-
up and for study 
details 




data recording and 
transfer prior to 
release of final 








4 times per day 













Users found app easy to 
use (4.75±0.46, intended 
to use it in the future 
(4.37±1.06) and found it 
easy to integrate into daily 
routine (4.5±1.07) 
 
Pts found app easy to 
use and would 
consider using app in 
the future 
 
Need larger study to 
determine feasibility 
in a diverse group of 
AF patients 
 
Small sample size 
 
Negative aspects of 







Pilot study to assess 
the feasibility and 
usability of the Health 
Buddies App in AF 
patients 




AF pts.: Mean (SD) 
age 69.2y (3.7); 10 
(67%) male; 6 





Mean (SD) age 9.5y 
(3.0)  
 






Prospective feasibility pilot 
study 
 
1 hospital in Belgium, 
recruited as out-pt. or in-pt. 
 
Inclusion criteria: AF, on a 
NOAC, grandchild aged 5-
15 years, having a tablet, 
mobile phone or computer 
with internet access 
 
Exclusion criteria: enrolled 
in other studies; non-Dutch 
speaking 
 
Study conducted October 
2015 to August 2016 
 
Participants had to use the 




Health Buddies App App co-developed 
with pts., 
grandchildren and 




















Goal to complete 
as many 
challenges as 
possible in 3 
months.  Reward 
at end trip or fun 
activity 
 
NOAC stock with 














































Patient knowledge on AF 
and treatment: JAKQ 
score improved but not 
significantly from 64.6% 
(SD 14.7) at baseline to 




Mean (SD) MMAS-8: at 
baseline 7.7 (0.6) and 7.4 
(0.9) at end of study  
Electronic monitoring 
showed lower taking and 
regimen adherence than 
self-reported on app 
(taking adherence 88.6% 
(SD 15.4) and regime 
adherence 81.8% (SD 
18.7).  Pill count 
adherence 94.5% (SD 9.2) 
 
Motivation to use app: 
App use significantly 
decreased towards end of 
study in both pts (p=0.009) 
and grandchildren 
(p<0.001). 13/15 (87%) 
completed the 90-day 
contract 
Mean (SD) % of days 
using app significantly 
higher in pts vs. 
grandchildren (57.7% (SD 




App experience: Rated 
positively on clarity 
(1.500), novelty (0.942) 
and stimulation (0.923) 
Small sample; 
selected sample (only 
15 participated); no 
control group 
 
Patients evaluated the 
educational aspect of 
this app as a capital 
gain 
 







and attractiveness (0.859).  
Efficiency (0.577) and 
dependability (0.481) 
received neutral rating 
ACC, American College of Cardiology; AF, atrial fibrillation; AFA, Atrial Fibrillation Association; AFEQT, Atrial Fibrillation Evaluation of QualiTy of life questionnaire; 
AHA, American Heart Association; CDSS, computerised decision support system; DCCV, direct current cardioversion; ECG, electrocardiogram; EHRA, European Heart 
Rhythm Association; FU, follow-up; HCP, healthcare professional; IQR, interquartile range; JAKQ, Jessa Atrial Fibrillation Questionnaire; mAFA, Mobile Atrial Fibrillation 
App; NOAC, non-vitamin K antagonist oral anticoagulant; NR, not reported; OAC, oral anticoagulation; pts, patients; PAF, paroxysmal atrial fibrillation; PVI, pulmonary 
vein isolation; QoL, quality of life; SD, standard deviation, UC, usual care; UEQ, User Experience Questionnaire; y, years 





Table 2: Risk of bias assessment for included studies 
Randomised controlled trials (assessed by Cochrane Risk of Bias tool8) 















Other sources of bias 
Desteghe 
(2018)4 
High High Unclear High Unclear Low Unclear 
Guo (2017)6 
 
Unclear Unclear Unclear High Low High Unclear 
 
Observational studies (assessed by Risk of Bias for non-randomised studies (RoBANS) tool9) 
Study Selection bias Confounding variables Performance bias Detection bias Attrition bias Reporting bias 
Author 
(year) 
 Inadequate confirmation 





Inadequate blinding of 
outcome assessments 
Incomplete outcome data Selective outcome reporting 
Balsam 
201912 
Low Unclear Low High Unclear High 
Hirschey 
201814 
High High High Unclear High High 
Sheibani 
201715 
Unclear Low Low High Low Low 
Ghanbari 
201713 
High High Low Unclear Unclear Unclear 
Desteghe 
20175 
High High Low Unclear Low Unclear 
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Study aim Study design Study 
population 






To investigate the 
effectiveness of an 
integrated care 
approach to AF 
management, 
supported by mobile 
health technology 
Prospective cluster-
RCT (40 sites) 
Intervention vs. 
usual care 








App (mAFA) II 
Smartphone app 
Upgraded version of mAF app6 





materials, patient involvement 
strategies with self-care 
protocols and structured follow-
up, to support implementation 
of ABC pathway 
 






of AF in 2 weeks; 







To evaluate the 




and OAC adherence 
and implementation 





to address patient 


































ABC, Avoid stroke, Better symptom management, and Cardiovascular and other comorbidities management; AF, atrial fibrillation; AF-LITT, Atrial Fibrillation health Literacy Information 
Technology Trial; ECA, Embodied Conversational Agent; HRQoL, health-related quality of life; mAFA, Mobile Atrial Fibrillation App; OAC, oral anticoagulation; PPG, 
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